Luke Halpern, Assistant Editor

The FDA approved treosulfan, in combination with fludarabine, for patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Engaging with the community, providing transparent information to patients, and using noncoercive methods of encouragement are strategies to reduce COVID-19 vaccine hesitancy.

A series of patient cases demonstrates the potential harm that patients with chronic inflammatory demyelinating polyneuropathy (CIDP) may face when transitioning from intravenous immunoglobulin (IVIG) to FcRn therapy.

Multiple treatments have been approved by regulators for the treatment of hemophilia A and B, giving pharmacists options for their patients.

Admissions to the hospital for fever were reduced in pediatric patients with medium-risk ALL receiving intravenous immunoglobulin, a potentially useful finding to help prevent infections in vulnerable patients.

These drugs are set to revolutionize their respective disease states in 2025.

Acalabrutinib with bendamustine and rituximab shows efficacy in patients with untreated mantel cell lymphoma by increasing progression-free survival in the ECHO trial.

The finding could help better treat patients with long COVID, as pharmacists and treatment providers can look out for ME/CFS symptoms.

Jim Dente of Advanced Pharmacy Solutions emphasizes the growing role of automation, artificial intelligence, and patient-centric business models in streamlining operations, improving patient care, and addressing industry challenges such as staff burnout and medication errors.

Building on a previous report that revealed corrupt business practices among the big 3 PBMs, a second interim report finds that PBMs heightened prices for important specialty generic drugs to increase their profit margins.

New data shows that, in high-risk patients with advanced cutaneous squamous cell carcinoma, cemiplimab reduces the risk of disease recurrence and death.

These drugs are set to revolutionize their respective disease states in 2025.

A new indication for the antibody-drug conjugate expands the future clinical potential of the treatment in patients with the rare breast cancer.

Managing comorbidities, ensuring proper dosing, and treating IVIG-related adverse events are areas where pharmacists play a large role.

Some patients treated with prolonged courses of oral nirmatrelvir/ritonavir experienced long COVID symptom improvements, while others reported little to no changes in their symptoms.

ALG-801 could present new opportunities to improve treatment and management of patients with pulmonary arterial hypertension, a life-threatening condition.

These new regulatory developments put CUTX-101 on track to become the first FDA-approved treatment for patients with Menkes disease.

For patients with multiple myeloma who may experience an infection while receiving teclistamab, supplementation with intravenous immunoglobulin (IVIG) can help resolve and prevent serious complications.

The new designation for the selective PPAR⍺ antagonist follows positive phase 1b/2 clinical trial results.

Regulatory action could help patients with Hunter syndrome who have cognitive and behavioral complications and often do not have an effective treatment crossing the blood-brain barrier.

Data from a follow-up at 6 months show a reduced risk of all-cause mortality in heart attack patients with anemia who receive a liberal transfusion strategy compared with a restrictive one.

COVID-19 survivors deemed the most highly impacted and fearful also reported the lowest health-related quality of life scores, indicating an association.

Backed by positive results in multiple clinical trials, a new drug application (NDA) has been submitted for relacorilant for consideration by the FDA.

Treatment with IVIG leads to high responses 6 months following the initiation of therapy.

Pharmacists should be aware of the impacts that anemia in patients being treated for cancer has on daily activities and overall quality of life.

Over 70% of children and young people with long COVID reported improvements in their symptoms within 24 months of their initial positive SARS-CoV-2 test.

The regulatory decision marks a significant step forward in the treatment of non-tuberculous mycobacteria infections.

Constantine Tam, MD, discusses zanubrutinib's efficacy in CLL/SLL, emphasizing its durability, high response rates, safety considerations, and evolving therapeutic potential in combination with other agents.

Study results show that the updated BNT162b2 XBB vaccine is effective in preventing hospitalizations or emergency department visits associated with COVID-19 complications.

Yi Lin, MD, PhD, highlights the importance of achieving MRD negativity in multiple myeloma, CAR T-cell therapy outcomes, and the critical role of pharmacists in patient care.